{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:30:27Z","timestamp":1784565027885,"version":"3.55.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T00:00:00Z","timestamp":1485993600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.drugalcdep.2016.12.001","type":"journal-article","created":{"date-parts":[[2017,3,29]],"date-time":"2017-03-29T03:18:01Z","timestamp":1490757481000},"page":"S48-S54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"S1","title":["The Prescription Opioid Addiction Treatment Study: What have we learned"],"prefix":"10.1016","volume":"173","author":[{"given":"Roger D.","family":"Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0005","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1001\/archpsyc.65.2.135","article-title":"An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study","volume":"65","author":"Anton","year":"2008","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0010","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jsat.2010.05.004","article-title":"Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: national surveys of physicians","volume":"39","author":"Arfken","year":"2010","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/10550490902772470","article-title":"Pain and substance-related pain-reduction behaviors among opioid dependent individuals seeking methadone maintenance treatment","volume":"18","author":"Barry","year":"2009","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004714-199502000-00008","article-title":"Buprenorphine treatment of refractory depression","volume":"15","author":"Bodkin","year":"1995","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0025","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2016.16070792","article-title":"The role of behavioral interventions in buprenorphine maintenance treatment: a review","author":"Carroll","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0030","unstructured":"Center for Behavioral Health Statistics and Quality, 2015. Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health, NSDUH Series H-50, HHS Publication No. SMA 15-4927."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0035","series-title":"The CBHSQ Report: Emergency Department Visits Involving Narcotic Pain Relievers, Substance Abuse and Mental Health Services Administration","author":"Crane","year":"2015"},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0040","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2012.12.010","article-title":"Patient characteristics associated with buprenorphine\/naloxone treatment outcome for prescription opioid dependence: results from a multisite study","volume":"131","author":"Dreifuss","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0045","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.drugalcdep.2015.02.033","article-title":"Characterizing opioid withdrawal during double-blind buprenorphine detoxification","volume":"151","author":"Dunn","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0050","series-title":"Standard Medication Management for Bup\/Nx Treatment of Opioid Analgesic Dependence for Use in NIDA CTN-0030 Unpublished Manual","author":"Fiellin","year":"1999"},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0055","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJMoa055255","article-title":"Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence","volume":"355","author":"Fiellin","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0060","doi-asserted-by":"crossref","first-page":"74.e11","DOI":"10.1016\/j.amjmed.2012.07.005","article-title":"A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine","volume":"126","author":"Fiellin","year":"2013","journal-title":"Am. J. Med."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0065","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1001\/jamainternmed.2014.5302","article-title":"Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial","volume":"174","author":"Fiellin","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0070","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa022164","article-title":"Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone","volume":"349","author":"Fudala","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0075","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/00952990.2013.842241","article-title":"Baseline characteristics and treatment outcomes in prescription opioid dependent patients with and without co-occurring psychiatric disorder","volume":"40","author":"Griffin","year":"2014","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0080","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.drugalcdep.2007.11.021","article-title":"A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification","volume":"94","author":"Gruber","year":"2008","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0085","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1176\/appi.ajp.2010.10050755","article-title":"Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking","volume":"168","author":"Johnson","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0090","first-page":"719","article-title":"Vital signs: demographic and substance use trends among heroin users\u2014United States, 2002\u20132013","volume":"64","author":"Jones","year":"2015","journal-title":"Morb. Mortal. Wkly. Rep. (MMWR)"},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0095","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.drugalcdep.2013.01.007","article-title":"Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers\u2014United States, 2002\u20132004 and 2008\u20132010","volume":"132","author":"Jones","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0100","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00002508-200409000-00005","article-title":"Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain","volume":"20","author":"Keller","year":"2004","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0105","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1176\/appi.ajp.2013.13081014","article-title":"Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism","volume":"171","author":"Kranzler","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0110","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0115","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jsat.2015.06.010","article-title":"Office-based opioid treatment with buprenorphine (OBOT-B): statewide implementation of the Massachusetts Collaborative Care Model in community health centers","volume":"60","author":"LaBelle","year":"2016","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0120","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders","volume":"374","author":"Lee","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0125","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1360-0443.1998.9344753.x","article-title":"Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial","volume":"93","author":"Ling","year":"1998","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0130","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/add.12266","article-title":"Comparison of behavioral treatment conditions in buprenorphine maintenance","volume":"108","author":"Ling","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0135","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0140","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4088\/JCP.14m09096","article-title":"Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population","volume":"76","author":"McDermott","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0145","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0740-5472(92)90062-S","article-title":"The fifth edition of the Addiction Severity Index","volume":"9","author":"McLellan","year":"1992","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0150","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1001\/jama.1993.03500150065028","article-title":"The effects of psychosocial services in substance abuse treatment","volume":"269","author":"McLellan","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0155","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11606-007-0129-0","article-title":"Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients","volume":"22","author":"Moore","year":"2007","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0160","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jsat.2016.08.016","article-title":"Cognitive Behavioral Therapy improves treatment outcomes for prescription opioid users in primary care buprenorphine treatment","volume":"71","author":"Moore","year":"2016","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0165","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/ADM.0b013e318277e92e","article-title":"A comparison of buprenorphine taper outcomes between prescription opioid and heroin users","volume":"7","author":"Nielsen","year":"2013","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0170","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/JCP.0b013e31818638a4","article-title":"Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy","volume":"28","author":"Nyhuis","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0175","series-title":"Manual for Enhanced Medical Management of Opioid Dependence with Buprenorphine. Unpublished Manuscript","author":"Pantalon","year":"1999"},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0180","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/10550490701862902","article-title":"Physical pain and associated clinical characteristics in treatment-seeking patients in four substance use disorder treatment modalities","volume":"17","author":"Potter","year":"2008","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0185","doi-asserted-by":"crossref","first-page":"605","DOI":"10.15288\/jsad.2013.74.605","article-title":"Buprenorphine\/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START)","volume":"74","author":"Potter","year":"2013","journal-title":"J. Stud. Alcohol Drugs"},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0190","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jsat.2014.07.009","article-title":"The multi-site prescription opioid addiction treatment study: 18-month outcomes","volume":"48","author":"Potter","year":"2015","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0195","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.289.18.2370","article-title":"Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities","volume":"289","author":"Rosenblum","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0200","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.drugalcdep.2007.02.012","article-title":"Prescription opioid abuse among enrollees into methadone maintenance treatment","volume":"90","author":"Rosenblum","year":"2007","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0205","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.15585\/mmwr.mm6450a3","article-title":"Increases in drug and opioid overdose deaths\u2014United States, 2000\u20132014","volume":"64","author":"Rudd","year":"2016","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0210","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jsat.2011.01.008","article-title":"Interim methadone treatment compared to standard methadone treatment: 4-month findings","volume":"41","author":"Schwartz","year":"2011","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0215","series-title":"Opiate Dependence: Origins and Treatment","first-page":"185","article-title":"A 48-week study of methadone, methadyl acetate and minimal services","author":"Senay","year":"1973"},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0220","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jamapsychiatry.2013.2216","article-title":"A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers","volume":"70","author":"Sigmon","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0225","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/10550490600625624","article-title":"Characterizing the emerging population of prescription opioid abusers","volume":"15","author":"Sigmon","year":"2006","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0230","series-title":"Measuring Alcohol Consumption: Psychosocial and Biochemical Methods","first-page":"41","article-title":"Timeline followback: a technique for assessing self-reported alcohol consumption","author":"Sobell","year":"1992"},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0235","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1525-1497.2005.0228.x","article-title":"Buprenorphine retention in primary care","volume":"20","author":"Stein","year":"2005","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0240","series-title":"Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-48, HHS Publication No. (SMA) 14-4863","author":"Substance Abuse, Mental Health Services Administration","year":"2014"},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0245","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jsat.2012.07.011","article-title":"Brief versus extended counseling along with buprenorphine\/naloxone for HIV-infected opioid dependent patients","volume":"43","author":"Tetrault","year":"2012","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0250","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1176\/appi.ps.201300256","article-title":"Medication-assisted treatment with buprenorphine: assessing the evidence","volume":"65","author":"Thomas","year":"2014","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0255","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.drugalcdep.2009.07.001","article-title":"Concurrent validation of the clinical opiate withdrawal scale (COWS) and single-item indices against the clinical institute narcotic assessment (CINA) opioid withdrawal instrument","volume":"105","author":"Tompkins","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0260","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0265","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1521-0391.2009.00017.x","article-title":"Conducting clinical research with prescription opioid dependence: defining the population","volume":"19","author":"Weiss","year":"2010","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0270","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial","volume":"68","author":"Weiss","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0275","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.drugalcdep.2014.04.005","article-title":"Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management?","volume":"140","author":"Weiss","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0280","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jsat.2014.03.004","article-title":"Reasons for opioid use among patients with dependence on prescription opioids: the role of chronic pain","volume":"47","author":"Weiss","year":"2014","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0285","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.02.030","article-title":"Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study","volume":"150","author":"Weiss","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2016.12.001_bib0290","unstructured":"World Health Organization, January 1997. Composite International Diagnostic Interview (CIDI): Core Version 2.1, Geneva, Switzerland."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871617300029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871617300029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T09:41:21Z","timestamp":1571910081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871617300029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":58,"alternative-id":["S0376871617300029"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.12.001","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Prescription Opioid Addiction Treatment Study: What have we learned","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}